Barbigerone Inhibits Tumor Angiogenesis, Growth and Metastasis in Melanoma

  • Yang, Jian-Hong (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Hu, Jia (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) ;
  • Wan, Li (State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine, The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicine, Chengdu University of Traditional Chinese Medicine) ;
  • Chen, Li-Juan (Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
  • Published : 2014.01.15


Tumor angiogenesis, growth and metastasis are three closely related processes. We therefore investigated the effects of barbigerone on all three in the B16F10 tumor model established in both zebrafish and mouse models, and explored underlying molecular mechanisms. In vitro, barbigerone inhibited B16F10 cell proliferation, survival, migration and invasion and suppressed human umbilical vascular endothelial cell migration, invasion and tube formation in concentration-dependent manners. In the transgenic zebrafish model, treatment with $10{\mu}M$ barbigerone remarkably inhibited angiogenesis and tumor-associated angiogenesis by reducing blood vessel development more than 90%. In vivo, barbigerone significantly suppressed angiogenesis as measured by H and E staining of matrigel plugs and CD31 staining of B16F10 melanoma tumors in C57BL/6 mice. Furthermore, it exhibited highly potent activity at inhibiting tumor growth and metastasis to the lung of B16F10 melanoma cells injected into C57BL/6 mice. Western blotting revealed that barbigerone inhibited phosphorylation of AKT, FAK and MAPK family members, including ERK, JNK, and p38 MAPKs, in B16F10 cells mainly through the MEK3/6/p38 MAPK signaling pathway. These findings suggested for the first time that barbigerone could inhibit tumor-angiogenesis, tumor growth and lung metastasis via downregulation of the MEK3/6/p38 MAPK signaling pathway. The findings support further investigation of barbigerone as a potential anti-cancer drug.


Supported by : National Natural Science Foundation of China


  1. Amundadottir LT, Leder P (1998). Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene, 16, 737-46.
  2. Carmeliet P (2003). Angiogenesis in health and disease. Nat Med, 9, 653-60.
  3. Carmeliet P, Base M (2008). Metabolism and therapeutic angiogenesis. N Engl J Med, 358, 2511-2.
  4. Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-57.
  5. Davidson B, Konstantinovsky S, Kleinberg L, et al (2006). The mitogen-activated protein kinases (MAPK). p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol, 102, 453-61.
  6. Fan TP, Yeh JC, Leung KW, Yue PY, Wong RN (2006). Angiogenesis: from plants to blood vessels. Trends Pharmacol Sci, 27, 297-309.
  7. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74.
  8. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
  9. Folkman J, Shing Y (1992). Angiogenesis. J Biol Chem, 267, 10931-4.
  10. Gupta GP, Massague J (2006). Cancer metastasis: building a framework. Cell, 127, 679-95.
  11. Johnson GL, Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911-2.
  12. Hsia DA, Mitra SK, Hauck CR, et al (2003). Differential regulation of cell motility and invasion by FAK. J Cell Biol, 160, 753-67.
  13. Huang D, Ding Y, Luo WM, et al (2008). Inhibition of MAPK Kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res, 68, 81-8.
  14. Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD (2001). Approaches to preclinical screening of antiangiogenic agents. Semin Oncol, 28, 570-6.
  15. Lee JC, Laydon JT, Mcdonnell PC, et al (1994). A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739-46.
  16. Li X, Wang X, Ye H, Peng A, Chen L (2012). Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-smallcell lung cancer xenografts growth through VEGFR2 signaling pathways.Cancer Chemother Pharmacol, 70, 425-37.
  17. Olson MF, Sahai E (2009). The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis, 26, 273-87.
  18. Patan S (2004). Vasculogenesis and angiogenesis. Cancer Treat Res, 117, 3-32.
  19. Raingeaud J, Gupta S, Rogers JS, et al (1995). Pro-inflammatory cytokines and environmental stress cause p38 mitogenactivated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem, 31, 270, 7420-6.
  20. Reddy KB, Nabha SM, Atanaskova N (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 22, 395-403.
  21. Small JV, Rottner K, Kaverina I, Anderson KI (1998). Assembling an actin cytoskeleton for cell attachment and movement. Biochim Biophys Acta, 1404, 271-81.
  22. Tournaire R, Simon MP, le Noble F, et al (2004). A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep, 5, 262-7.
  23. Tozer GM, Kanthou C, Baguley BC (2005). Disrupting tumor blood vessels. Nat Rev Cancer, 5, 423-35.
  24. Uzgare AR, Kaplan PJ, Greenberg NM (2003). Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate, 55, 128-39.
  25. Vicent S, Garayoa M, Lopez-Picazo JM, et al (2004). Mitogenactivated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res, 10, 3639-49.
  26. Vilain C (1980). Barbigerone, a new pyranoisoflavone from seeds of Tephrosia barbigera. Phytochem, 19, 988-9.
  27. Wangensteen H, Alamgir M, Rajia S, Samuelsen AB, Malterud KE (2005). Rotenoids and isoflavones from Sarcolobus globosus. Planta Med, 71, 754-8.
  28. Wangensteen H, Miron A, Alamgir M, et al (2006). Antioxidant and 15-lipoxygenase inhibitory activity of rotenoids, isoflavones and phenolic glycosides from Sarcolobus globosus. Fitoterapia, 77, 290-5.
  29. Webb CP, Van Aelst L, Wigler MH, Woude GF (1998). Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA, 95, 8773-8.
  30. Ye HY, Zhong SJ, Li YF, et al (2010). Enrichment and isolation of barbigerone from Millettia pachycarpa Benth. using highspeed counter-current chromatography and preparative HPLC. J Sep Sci, 33, 1010-7.
  31. Yenesew A, Derese S, Midiwo JO, Oketch-Rabah HA, Lisgarten J, Palmer R, et al (2003). Anti-plasmodial activities and X-ray crystal structures of rotenoids from Millettia usaramensis subspecies usaramensis". Phytochem, 64, 773-9.
  32. Yenesew A, Midiwo JO, Waterman PG (1998). Rotenoids, isoflavones and chalcones from the stem bark of Millettia usaramensis subspecies usaramensis. Phytochem, 47, 295-300.
  33. Zhao CJ, Yang HS, Shi HS, et al (2011). Distinct Contributions of Angiogenesis and Vascular Co-option during the Initiation of Microtumors and Micrometastases. Carcinogenesis, 32, 1143-50.
  34. Zhang D, Li B, Shi J, et al (2010). Suppression of Tumor Growth and Metastasis by Simultaneously Blocking Vascular Endothelial Growth Factor (VEGF).-A and VEGF-C with a Receptor-Immunoglobulin Fusion Protein. Cancer Res, 70, 2495-503.

Cited by

  1. Biological Screening of Novel Derivatives of Valproic Acid for Anticancer and Antiangiogenic Properties vol.15, pp.18, 2014,
  2. Different Immunology Mechanisms of Phellinus igniarius in Inhibiting Growth of Liver Cancer and Melanoma Cells vol.15, pp.8, 2014,
  3. The promise of zebrafish as a chemical screening tool in cancer therapy vol.7, pp.11, 2015,
  4. Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomal nanoparticle: preparation, characterization and anti-cancer activities vol.82, pp.3-4, 2015,
  5. Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges vol.23, pp.6, 2016,
  6. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors vol.57, pp.2, 2017,
  7. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling vol.60, pp.2, 2017,
  8. New insights into the antiangiogenic and proangiogenic properties of dietary polyphenols vol.61, pp.6, 2017,
  9. Macrophages enhance Vegfa-driven angiogenesis in an embryonic zebrafish tumour xenograft model vol.11, pp.12, 2018,